OpenAI Releases Its Drug Discovery Model. Amazon Opens the Biology Platform.
Last week we tracked capital concentrating fast — Rock Health's Q1 data confirmed $4 billion raised in digital health in a single quarter, sixty percent of it landing in just twelve transactions. The platforms capturing investment are the ones that have already crossed from evaluation to infrastructure. This week, two of the largest technology companies in the world decided they would build that infrastructure themselves.OpenAI launched GPT-Rosalind, its first domain-specific reasoning model, built for drug discovery and named after Rosalind Franklin. The same week, Amazon Web Services launched Amazon Bio Discovery — a platform of more than 40 biological foundation models connected directly to wet lab partners for physical validation of computationally designed candidates. Novo Nordisk anchored OpenAI's pharma ambitions with a company-wide integration spanning drug discovery, manufacturing, supply chain, and commercial operations.Seven weeks ago we covered Anthropic acquiring a small biology team. This week, the products arrived.
